News
Veeva Becomes First Public Company to Convert to a Public Benefit Corporation
Veeva Systems (NYSE: VEEV) announced that in an overwhelming majority vote, 99% of voting shareholders support the company’s proposal to become a public benefit corporation (PBC), including the
CORRECTING and REPLACING Veeva Becomes First Public Company to Convert to a Public Benefit Corporation
Please replace the release with the following corrected version due to multiple revisions.
The updated release reads:
VEEVA BECOMES FIRST PUBLIC COMPANY TO CONVERT TO A PUBLIC BENEFIT
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
Pfizer Inc. (NYSE: PFE) today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth
Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling
With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company’s
New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale
Illumina, Inc. (NASDAQ: ILMN) is transforming genomic data bottlenecks into catalysts with the launch of Illumina Connected Analytics (ICA). This new and integrated bioinformatics solution provides
Waters APGC-MS/MS System Accepted for Advanced Dioxin and Furan Analysis Following USEPA Approval of SGS AXYS Method 16130
Waters Corporation (NYSE:WAT) today announced that its Xevo TQ-XS atmospheric pressure gas chromatography (APGC) mass spectrometry (MS) platform is an accepted alternative for the identification
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2020 to
PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 66% and 63%
Humana Partners with Leading Ohio Nonprofits to Address Food Insecurity and Housing
Health and well-being company Humana Inc. (NYSE: HUM) today announced partnerships with several of Ohio’s leading community service organizations to address social factors that can significantly
Quidel Announces Preliminary Revenue for Fourth Quarter 2020; Will Present Virtually at 39th Annual J.P. Morgan Healthcare Conference
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects
PerkinElmer to Acquire Oxford Immunotec Global PLC
PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms
Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy
Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure
Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer leadership at the 39th Annual J.P. Morgan Healthcare Conference to be held
Dexcom to Present at 39th Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 39th annual J.P. Morgan Healthcare
US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 Vaccine, to the 27 European Union (EU)
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib) as
Quidel Receives Emergency Use Authorization for Moderately Complex Solana® SARS Molecular Test for COVID-19 Diagnosis
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has
Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 Vaccine from
Agilent Receives Approval for GenetiSure Dx Postnatal Assay in Japan
Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx Postnatal Assay – a microarray-based
Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 2, 2021. The
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
J.P. Morgan Virtual
Humana Inc. to Present at the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference: A View from the Top
Humana Inc. (NYSE: HUM) announced today that Bruce D. Broussard, President and Chief Executive Officer, will make a presentation to investors at the Goldman Sachs Annual Healthcare CEO Conference
Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer and BioNTech for COMIRNATY